← Leaderboards
Randall Brand
University Of Pittsburgh At Pittsburgh
$11,652,606
Attributed
$27,409,006
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,409,006 · 8
By mechanism
U01$24,284,775 · 5
R01$3,080,631 · 1
R13$43,600 · 2
Top collaborators
- Brian B Haab17 shared
- Surinder Kumar Batra16 shared
- Peter J Allen12 shared
- Dhiraj Yadav10 shared
- Anna E Lokshin5 shared
- Daniel W Chan3 shared
- Hui Zhang3 shared
- Zhen Zhang3 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Surinder Kumar Batra$34,830,369
- Mack T Ruffin$5,808,265
- Dhiraj Yadav$8,018,338
- Hernando Gomez Danies$1,500,888
- Yang Liu$8,494,764
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasSamplingBiological MarkersPancreasSuccessImageEarly DiagnosisOperative Surgical ProceduresDiagnosisCandidate MarkerResearch PersonnelValidationHigh RiskMalignant NeoplasmsLeadDesignPerformanceExcisionResourcesTumorBiomarker PanelAreaPancreatic DiseasesChronic Pancreatitis
Grant awards (48)
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$1,264,325
U01 · FY2025 · CA · contact PI
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions$809,563
U01 · FY2025 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$609,412
R01 · FY2025 · CA
PancreasFest 2025: Pancreas Disease Across the Lifespan$23,600
R13 · FY2025 · DK · contact PI
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$1,201,109
U01 · FY2024 · CA · contact PI
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions$769,085
U01 · FY2024 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$584,995
R01 · FY2024 · CA
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$457,915
U01 · FY2024 · DK
Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center$112,819
U01 · FY2024 · DK
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma$915,566
U01 · FY2023 · CA · contact PI
Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions$825,499
U01 · FY2023 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$622,418
R01 · FY2023 · CA
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$620,756
U01 · FY2023 · CA
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$476,995
U01 · FY2023 · DK
Consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Consortium â Pittsburgh Clinical Center$134,997
U01 · FY2023 · DK
PancreasFest 2023$20,000
R13 · FY2023 · DK · contact PI
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$643,951
U01 · FY2022 · CA
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$626,416
R01 · FY2022 · CA
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$476,995
U01 · FY2022 · DK
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$100,000
U01 · FY2022 · DK
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer$637,390
R01 · FY2021 · CA
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$625,227
U01 · FY2021 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$617,452
U01 · FY2021 · CA · contact PI
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$469,495
U01 · FY2021 · DK
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$374,611
U01 · FY2021 · CA
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$90,650
U01 · FY2021 · DK
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$875,414
U01 · FY2020 · CA · contact PI
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$671,698
U01 · FY2020 · CA
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$548,627
U01 · FY2020 · CA
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$469,495
U01 · FY2020 · DK
Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer: Pittsburgh Clinical Center$120,000
U01 · FY2020 · DK
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$857,224
U01 · FY2019 · CA · contact PI
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$617,734
U01 · FY2019 · CA
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$521,859
U01 · FY2019 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$1,563,388
U01 · FY2018 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$553,441
U01 · FY2018 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$1,537,769
U01 · FY2017 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$554,248
U01 · FY2017 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$129,694
U01 · FY2017 · CA · contact PI
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$902,819
U01 · FY2016 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$623,533
U01 · FY2016 · CA
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms$171,812
U01 · FY2016 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$101,267
U01 · FY2015 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$389,914
U01 · FY2014 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$530,069
U01 · FY2013 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$224,231
U01 · FY2012 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$601,107
U01 · FY2011 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$732,422
U01 · FY2010 · CA